Aevi Genomic Medicine LLC

Aevi Genomic Medicine — Medgenics — Investor Presentation (November 2014)

43 slides from Aevi Genomic Medicine's investor presentation, Nov 12, 2014

  1. Slide 1: Unlocking the potential of gene therapy for patients with rare and orphan diseases

    — Unlocking the potential of gene therapy for patients with rare and orphan diseases November 2014

  2. Slide 2: Forward Looking Statement

    Forward Looking Statement This presentation includes certain estimates and other forward - looking statements within the meaning of Section 21 E of the Securities Exchange Act of 1934 , as amended, including statements with respect to anticipated operating and financial performance, clinical results

  3. Slide 3: Investment Highlights

    Investment Highlights • Rare and Orphan disease focused company • Proof of concept established with TARGT e x vivo gene therapy platform as evidenced by the positive initial data of ongoing TARGT EPO clinical trial • Multiple commercially attractive orphan indications for TARGT EPO identified; data

  4. Slide 4: Management Team - Proven Track Record

    Management Team - Proven Track Record • President, Shire Specialty Pharmaceuticals - Responsible for all aspects of the $2.5 billion business e.g., commercial, R&D, manufacturing, etc. • President, Life Sciences, Safeguard Scientifics – Lead Life Sciences PE team, responsible for both investment and

  5. Slide 5: Medgenics Vision

    Medgenics Vision 5 Driven by our commitment to patients we strive to create the premier rare and orphan disease company by: x Developing first - to - market or best - in - class therapies that are transformative to patients suffering from life - altering rare genetic diseases x Having unparalleled u

  6. Slide 6: Medgenics Pipeline

    Medgenics Pipeline Product Program Area Preclinical Phase 1/2 Phase 2/3 Status TARGT EPO MDGN - 201 Chronic Renal Diseases and Hematological Disorders Renal Anemia - ESRD Ongoing Hypo - Responders to ESA Initiate Q1 15 Anemic CKD Transplant Initiate H1 15 Peritoneal Dialysis Initiate H1 15 Beta Thal

  7. Slide 7: TARGT (Transduced Autologous Restorative Gene Therapy)

    TARGT TM (Transduced Autologous Restorative Gene Therapy) 1. H arvest Micro - Organs from abdominal dermis using the proprietary DermaVac device 2. Transduce fibroblasts in Micro - Organs via ex vivo gene therapy to create TARGT EPO 3. Wash out HDAd vector, measure production and choose TARGT EPO fo

  8. Slide 8: Significant Improvements to Technology Platform

    Significant Improvements to Technology Platform 8 • Vector optimization • Culture conditions • Re - implantation technique • Engraftment The entire system was re - engineered to increase and stabilize secretion levels in vivo

  9. Slide 9: TARGT Platform Mimics the Natural System

    TARGT Platform Mimics the Natural System • Autologous proteins and peptides • Continuous secretion • Physiologic levels – Avoids supratherapeutic spikes • Precise, individualized dosing • Safe – Simple, well - tolerated procedure – Avoids exposure to viral antigen – Avoids viral DNA integration – In

  10. Slide 10: Phase 1/2 trial in ESRD Patients with Renal Anemia

    Phase 1/2 trial in ESRD Patients with Renal Anemia 10

  11. Slide 11: MDGN-201 Trial Design

    MDGN - 201 Trial 11 Prospective, Open - label, Dose Escalation study, to evaluate Safety and Efficacy (control of Hb 9 - 11 and < 12 g/ d L ) of TARGT EPO in ESRD patients Study Summary Group Treatment N A Low dose eEPO 18 - 25 IU/kg/day 3 + 3 * B Mid dose eEPO 35 - 45 IU/kg/day 3 + 3 * C High dose

  12. Slide 12: TARGT EPO Patient Profile

    TARGT EPO Patient Profile • End Stage Renal Disease (ESRD) patients – CKD patients with renal failure and low baseline eEPO secretion – Hemodialysis patients with inability to regulate body fluid levels • rHuEPO dependent – Require 2 - 3 injections on a weekly basis to maintain hemoglobin in target

  13. Slide 13: Patient One Run-in Period

    13 Patient One Run - in Period Supratherapeutic levels of rHuEPO required to maintain hemoglobin levels Days Pre-implantation -25 -20 -15 -10 -5 0 Serum rHuEPO, mIU/ml 0 200 400 600 800 1000 1200 Days Pre-implantation -25 -20 -15 -10 -5 0 Serum Hb, g/dL 8 9 10 11 12 13 Patient Description: Age: 70 S

  14. Slide 14: Patient One Interim Results

    14 Patient One Interim Results • 3 Transduced Micro - Organs (TARG T EPO ) implanted • Patient stabilizes after approximately 30 days • Target Hb is reached with approx 100x lower C MAX than rHuEPO • Patient appears to have the ability to auto regulate Hb levels • *Possible hemoconcentration Five mo

  15. Slide 15: Patient Two Interim Results

    15 Patient Two Interim Results • 2 Transduced Micro Organs (TARGT EPO ) implanted • Patient displays higher peak eEPO but stabilizes after 45 days • Target Hb is reached with approx 100 x lower C MAX than rHuEPO . Three months post implantation renal anemia is well controlled • Patient appears to ha

  16. Slide 16: Patient Three Interim Results

    Patient Three Interim Results Two months post implantation patient required rHuEPO • 1 Transduced Micro - Organ (TARGT EPO ) implanted • O nly patient to receive 1 TMO 16 • * Patient surgery : (not product related) * Days from implantation 0 10 20 30 40 50 60 70 Serum eEPO, mIU/ml 0 5 10 15 20 Predi

  17. Slide 17: Potential Paradigm Shift in Treatment of Renal Anemia

    Potential Paradigm Shift in Treatment of Renal Anemia • Duration: – P atients 1 and 2 are meeting target secretion profile of continuously producing physiologic levels of endogenous EPO sufficient to maintain target Hb • After complications unrelated to therapy patient 3 required rHuEPO • Hemoglobin

  18. Slide 18: Next Steps for MDGN-Trial

    Next Steps for MDGN - 201 Trial • Q 4 2014 – Complete enrollment in the low dose arm of trial ( 3 additional patients) • Q 1 2015 – Enroll 6 - patient cohort comparing single dose Depo - Medrol to multi - dose Depo - Medrol 18

  19. Slide 19: Orphan Indications for TARGT EPO

    Orphan Indications for TARGT EPO 19

  20. Slide 20: Overview of Orphan Indications for TARGT EPO

    Overview of Orphan Indications for TARGT EPO 20 • Renal Anemia/ESRD (3 indications) – Leverage current TARGT EPO IND for signal finding trials – Rapid route to market • Plan to de - risk programs through small signal finding studies (10 - 15 patients) – Interim results expected H2 2015 • Expect rela

  21. Slide 21: Orphan Indications – Renal Anemia/ESRD

    Orphan Indications – Renal Anemia/ESRD • Hypo - responders to rHuEPO – Patients unable to manage anemia on maximal dose of rHuEPO – Continuous physiologic levels of eEPO will stimulate bone marrow more effectively and safely than intermittent IV dosing 1 – Estimated US prevalence: ~ 40 , 000 - 70 ,

  22. Slide 22: Orphan Indications – Hematological Disorders

    Orphan Indications – Hematological Disorders • Beta Thalassemia Intermedia – Milder form of symptomatic beta thalassemia patients (e.g.,~12 transfusions/year) – rHuEPO has shown ability to reduce anemia and raise hemoglobin in beta thalassemia 1 ; safety issues have limited use – Estimated US/EU pre

  23. Slide 23: Additional Pipeline Opportunities

    Additional Pipeline Opportunities 23

  24. Slide 24: Novel Peptide Production Capability

    Novel Peptide Production Capability • TARGT system has demonstrated the unique ability to produce native peptides in vivo • Native peptides have been difficult to develop into drugs – Short half - life: poor metabolic stability and rapid clearance – Delicate: often require a complex manufacturing pr

  25. Slide 25: Glucagon-like peptide (GLP-2)

    Glucagon - like peptide 2 (GLP - 2) • 33 amino acid naturally occurring peptide, t 1/2 = 6 - 7 min • Produced by L cells of small intestine • Several important functions: – Increases intestinal absorption – Stimulates intestinal growth – Reduces bone breakdown • Improves intestinal absorption in hum

  26. Slide 26: TARGT GLP-2 vs teduglutide PK profile

    • TARGT GLP - 2 should provide a more favorable PK profile – physiologic levels of continuous GLP - 2 – lower peak dose and continuous coverage • Indications include short bowel syndrome and IBD • Pre - IND meeting in H 1 2015 MDGN TARGT GLP - 2 vs teduglutide 26 Source NPS briefing book, Gattex Adv

  27. Slide 27: MDGN GLP-2 Program

    MDGN GLP - 2 Program • We adapted the TARGT platform for expression of peptides < 40 amino acids including GLP - 2 • Program has advanced to in vivo stage in SCID mice (n=5) 27 0 5 10 15 20 25 30 7 18 27 39 49 60 Serum GLP - 2 ng/ml Days from Implantation

  28. Slide 28: Collaboration with Center for Applied Genomics (CAG)

    Collaboration with Center for Applied Genomics (CAG) 28

  29. Slide 29: Collaboration Structure

    Collaboration Structure • MDGN – E xclusive license to use the rare and orphan disease samples at the Center for Applied Genomics (CAG) at the Children’s Hospital of Philadelphia (CHOP) biobank for the purpose of developing and commercializing therapeutic treatments and diagnostic targets for rare a

  30. Slide 30: CHOP Center for Applied Genomics

    CHOP Center for Applied Genomics 30 • Founded by Dr. Hakon Hakonarson in 2006 • Highly regarded knowledge base and expertise – More than 3 5 0 publications in leading journals • Enriched database for Rare and Orphan diseases – 10 % of rare disease patients in North America treated at CHOP – Largest

  31. Slide 31: Leveraging the CAG Biobank

    Leveraging the CAG Biobank • Realizes Medgenics vision of having unparalleled understanding of the underlying science of rare diseases from phenotype to genotype – It is estimated that 80 % of Rare and Orphan diseases have a genetic origin • TARGT platform enables rapid prototyping of therapy • Effe

  32. Slide 32: Conclusion

    Conclusion • Proof of concept established with TARGT ex vivo gene therapy platform as evidenced by the positive initial data of ongoing TARGT EPO clinical trial • Multiple commercially attractive orphan indications for TARGT EPO identified; data from proof of concept studies expected in H2 2015 • Pl

  33. Slide 33: Company Development Timeline

    Company Development Timeline 33 Long term ( 2018 ) ▪ Multiple late - stage clinical programs ▪ First commercial product launch (TARGT EPO ) Mid term ( 2016 - 2017 ) ▪ P ivotal trials for multiple TARGT EPO indications ▪ Proof of concept for GLP - 2 ▪ INDs for 4 early pipeline programs Short term (20

  34. Slide 34: Upcoming Catalysts

    Upcoming Catalysts 34 TIMING Complete enrollment in MDGN - 201 study Q4 14 Initiate Phase 2 study in Hypo - Responders Q1 15 Initiate Phase 2 study in Anemic CKD Transplant H1 15 Initiate Phase 2 study in Peritoneal Dialysis H1 15 Initiate Phase 2 study in Beta Thalassemia Intermedia H1 15 Initiate

  35. Slide 35: Financial Summary

    Financial Summary • NYSE - MKT: MDGN • Basic shares outstanding – 18.9 M • Warrants and options – 9 M warrants – 7 M options • Cash runway – $ 15 M at September 2014 – Cash burn of ~ $ 1 M per month 35

  36. Slide 36: APPENDIX

    APPENDIX ss medgenics

  37. Slide 37: Gen 1 System: eEPO Production Drops Off Rapidly

    0 5 10 15 20 25 30 -10 0 10 20 30 40 50 60 70 Serum e EPO , mU /ml Days from implantation Gen 1 System: eEPO Production Drops O ff Rapidly • Excellent safety and tolerability profile • One month of erythropoietin production translates into 4 – 5 months of anemia treatment given lifespan of red blood

  38. Slide 38: Bulk of Diagnosed CKD Patients in Stage III-V (ESRD)

    Bulk of Diagnosed CKD Patients in Stage III - V (ESRD) - 2.0 4.0 6.0 8.0 10.0 12.0 14.0 I II III IV V- ESRD Patients MM Stage US CKD Population 38 - 400 800 1,200 1,600 I II III IV V - ESRD Patients 000 ’s Stage Diagnosed Population • The US CKD patient population is approximately 26 million • The m

  39. Slide 39: TARGT EPO in Hypo-responders to rHuEPO

    TARGT EPO in Hypo - responders to rHuEPO 39 • Clinical Rationale – Continuous physiologic levels of eEPO will stimulate bone marrow more effectively and safely than intermittent IV dosing 1 • Commercial Rationale: – Identified orphan population of high unmet need – Reduction of overall patient costs

  40. Slide 40: Hypo-Responsive to rHuEPO Patient Flow

    Hypo - Responsive to rHuEPO Patient Flow 40 600K ESRD Patients ~ 40 - 70K Hypo - Responsive ESRD patients ~ 366 K ESRD patients on ESA • Estimated cost of at least $ 30 K/year for anemia management • > $ 20 K/year rHuEPO • $ 5 - 10 K/year in transfusion costs Source: USRDS database and primary compa

  41. Slide 41: Beta Thalassemia

    Beta Thalassemia 41 • Beta Thalassemia is the most common genetic disease worldwide – Yet, it represents an Orphan disorder with significant unmet need • Characteristics in symptomatic patients include 1 : – Severe anemia – Iron overload – Splenomegaly • Patients generally require transfusions and/o

  42. Slide 42: TARGT EPO in Beta Thalassemia Intermedia

    TARGT EPO in Beta Thalassemia Intermedia 42 • Clinical Rationale: – eEPO levels are lower than expected in Beta Thalassemia patients ▪ rHuEPO has shown the ability to reduce transfusions and increase hemoglobin levels in Beta Thalassemia patients 1 ▪ Safety concerns have limited usage of rHuEPO – Co

  43. Slide 43: Beta Thalassemia Intermedia Patient Flow

    Beta Thalassemia Intermedia Patient Flow 43 ~100,000 Symptomatic Beta Thalassemia patients W.W. ~ 50,000 Beta Thalassemia Intermedia patients W.W. ~ 15,500 Beta Thalassemia Intermedia Patients US/EU • Avg. cost of ~$ 100 K/year* • ~$ 60 K/year in transfusion costs • (> 12 units of blood per year) •

Medgenics — Investor Presentation (November 2014) on 6ix